Favourable outcome of coronavirus disease 2019 in a patient with anaplastic lymphoma kinase-positive non-small-cell lung cancer receiving alectinib

MeSH terms

• Aged
• Anaplastic Lymphoma Kinase / antagonists & inhibitors
• Anaplastic Lymphoma Kinase / metabolism
• Anti-HIV Agents / therapeutic use
• Betacoronavirus / isolation & purification
• COVID-19
• COVID-19 Drug Treatment
• Carbazoles / pharmacology
• Carbazoles / therapeutic use*
• Carcinoma, Non-Small-Cell Lung / complications
• Carcinoma, Non-Small-Cell Lung / diagnosis
• Carcinoma, Non-Small-Cell Lung / drug therapy*
• Carcinoma, Non-Small-Cell Lung / pathology
• Coronavirus Infections / complications
• Coronavirus Infections / diagnosis
• Coronavirus Infections / drug therapy
• Coronavirus Infections / therapy*
• Coronavirus Infections / virology
• Drug Combinations
• Humans
• Hydroxychloroquine / therapeutic use
• Lopinavir / therapeutic use
• Lung / diagnostic imaging
• Lung Neoplasms / complications
• Lung Neoplasms / diagnosis
• Lung Neoplasms / drug therapy*
• Lung Neoplasms / pathology
• Male
• Masks
• Noninvasive Ventilation / instrumentation
• Pandemics
• Piperidines / pharmacology
• Piperidines / therapeutic use*
• Pneumonia, Viral / complications
• Pneumonia, Viral / diagnosis
• Pneumonia, Viral / therapy*
• Pneumonia, Viral / virology
• Ritonavir / therapeutic use
• SARS-CoV-2
• Tomography, X-Ray Computed
• Treatment Outcome